{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:10:37Z","timestamp":1789431037831,"version":"build-2803163510"},"reference-count":81,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,15]]},"DOI":"10.1093\/ibd\/izy150","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T10:55:49Z","timestamp":1526554549000},"page":"2173-2182","source":"Crossref","is-referenced-by-count":105,"title":["Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention"],"prefix":"10.1093","volume":"24","author":[{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"first","affiliation":[{"name":"Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,17]]},"reference":[{"key":"key\n\t\t\t\t20180915041322_CIT0001","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180915041322_CIT0002","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1097\/MIB.0000000000000902","article-title":"Management and prevention of herpes zoster in the immunocompromised inflammatory bowel disease patient: a clinical quandary","volume":"22","author":"C\u00f4t\u00e9-Daigneault","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0003","doi-asserted-by":"crossref","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"key\n\t\t\t\t20180915041322_CIT0004","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1473-3099(03)00857-0","article-title":"What does epidemiology tell us about risk factors for herpes zoster","volume":"4","author":"Thomas","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6611a1","article-title":"Surveillance of vaccination coverage among adult populations - United States, 2015","volume":"66","author":"Williams","year":"2017","journal-title":"MMWR Surveill Summ"},{"key":"key\n\t\t\t\t20180915041322_CIT0006","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/ecco-jcc\/jjv064","article-title":"Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake","volume":"9","author":"Malhi","year":"2015","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180915041322_CIT0007","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180915041322_CIT0008","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/003655298750027290","article-title":"Azathioprine: state of the art in inflammatory bowel disease","volume":"225","author":"Sandborn","year":"1998","journal-title":"Scand J Gastroenterol Suppl"},{"key":"key\n\t\t\t\t20180915041322_CIT0009","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180915041322_CIT0010","doi-asserted-by":"crossref","first-page":"G155","DOI":"10.1152\/ajpgi.00311.2015","article-title":"JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines","volume":"310","author":"Danese","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"key\n\t\t\t\t20180915041322_CIT0011","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/ecco-jcc\/jjx003","article-title":"The future of janus kinase inhibitors in inflammatory bowel disease","volume":"11","author":"De Vries","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180915041322_CIT0012","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180915041322_CIT0013","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180915041322_CIT0014","doi-asserted-by":"crossref","first-page":"ii67","DOI":"10.1136\/ard.2004.028290","article-title":"Targeting the Jak\/STAT pathway for immunosuppression","volume":"63","author":"O\u2019Shea","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0015","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"key\n\t\t\t\t20180915041322_CIT0016","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1046\/j.1365-2249.1997.4001304.x","article-title":"Jak3 activation in human lymphocyte precursor cells","volume":"108","author":"Sharfe","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"key\n\t\t\t\t20180915041322_CIT0017","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1128\/CMR.18.1.70-80.2005","article-title":"Preventing varicella-zoster disease","volume":"18","author":"Hambleton","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20180915041322_CIT0018","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180915041322_CIT0019","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40263-015-0261-z","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis","volume":"29","author":"Subei","year":"2015","journal-title":"CNSS Drugs"},{"key":"key\n\t\t\t\t20180915041322_CIT0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/IAI.32.1.24-27.1981","article-title":"Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged","volume":"32","author":"Berger","year":"1981","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20180915041322_CIT0021","first-page":"595","article-title":"T cell ageing: effects of age on development, survival & function","volume":"138","author":"Salam","year":"2013","journal-title":"Indian J Med Res"},{"key":"key\n\t\t\t\t20180915041322_CIT0022","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"key\n\t\t\t\t20180915041322_CIT0023","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1006\/smim.2001.0293","article-title":"Immune evasion as a pathogenic mechanism of varicella zoster virus","volume":"13","author":"Abendroth","year":"2001","journal-title":"Semin Immunol"},{"key":"key\n\t\t\t\t20180915041322_CIT0024","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1084\/jem.20040634","article-title":"Varicella-zoster virus transfer to skin by T cells and modulation of viral replication by epidermal cell interferon-alpha","volume":"200","author":"Ku","year":"2004","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20180915041322_CIT0025","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180915041322_CIT0026","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0027","first-page":"341","article-title":"VZV T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"key\n\t\t\t\t20180915041322_CIT0028","doi-asserted-by":"crossref","first-page":"9852","DOI":"10.1073\/pnas.1610253113","article-title":"Network pharmacology of JAK inhibitors","volume":"113","author":"Moodley","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20180915041322_CIT0029","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12895-015-0025-y","article-title":"Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis","volume":"15","author":"Valenzuela","year":"2015","journal-title":"BMC Dermatol"},{"key":"key\n\t\t\t\t20180915041322_CIT0030","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0031","doi-asserted-by":"crossref","first-page":"ofw205","DOI":"10.1093\/ofid\/ofw205","article-title":"Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and\/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis","volume":"3","author":"Marra","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0032","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t20180915041322_CIT0033","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","article-title":"Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease","volume":"4","author":"Gupta","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180915041322_CIT0034","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG clinical guideline: preventive care in inflammatory bowel disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180915041322_CIT0035","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/apt.12182","article-title":"Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease","volume":"37","author":"Long","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180915041322_CIT0036","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohn\u2019s disease","volume":"104","author":"Marehbian","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180915041322_CIT0037","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","article-title":"Incidence of herpes zoster in patients with altered immune function","volume":"42","author":"Chen","year":"2014","journal-title":"Infection"},{"key":"key\n\t\t\t\t20180915041322_CIT0038","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180915041322_CIT0039","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/ard.2009.125658","article-title":"Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists","volume":"69","author":"Garc\u00eda-Doval","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0040","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/jid.2011.383","article-title":"Risk of herpes zoster in patients receiving anti-TNF-\u03b1 in the prospective French RATIO registry","volume":"132","author":"Serac","year":"2012","journal-title":"J Invest Dermatol"},{"key":"key\n\t\t\t\t20180915041322_CIT0041","first-page":"271","article-title":"Varicella zoster virus encephalitis during treatment with anti-tumor necrosis factor-alpha agent in a psoriatic arthritis patient","volume":"33","author":"Buccoliero","year":"2010","journal-title":"New Microbiol"},{"key":"key\n\t\t\t\t20180915041322_CIT0042","first-page":"54","article-title":"Disseminated varicella zoster virus infection with encephalitis in a UC patient receiving infliximab","volume":"9","author":"Elwir","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"key\n\t\t\t\t20180915041322_CIT0043","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180915041322_CIT0044","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180915041322_CIT0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0046","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39473","article-title":"VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180915041322_CIT0047","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0048","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0049","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180915041322_CIT0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180915041322_CIT0051","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0052","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S0016-5085(17)34357-3","article-title":"Safety and efficacy of ABT-494 (Upadacitinib), an oral Jak1 inhibitor, as induction therapy in patients with Crohn\u2019s disease: results from Celest","volume":"152","author":"Sandborn","year":"2017","journal-title":"Gastroenterol"},{"key":"key\n\t\t\t\t20180915041322_CIT0053","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180915041322_CIT0054","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180915041322_CIT0055","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12879-017-2185-3","article-title":"Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia","volume":"17","author":"Friesen","year":"2017","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0056","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2017.03.023","article-title":"Herpes zoster in psoriasis patients treated with tofacitinib","volume":"77","author":"Winthrop","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t20180915041322_CIT0057","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/jmv.22182","article-title":"Possible association of lower rate of postherpetic neuralgia in patients on anti-tumor necrosis factor-\u03b1","volume":"83","author":"Javed","year":"2011","journal-title":"J Med Virol"},{"key":"key\n\t\t\t\t20180915041322_CIT0058","first-page":"566","article-title":"Genome-wide trans-ancestry meta-analysis of herpes zoster in RA and Pso patients treated with tofacitinib","volume":"67","author":"Bing","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180915041322_CIT0059","volume-title":"Zostavax FDA approval","author":"US Food and Drug Administration"},{"key":"key\n\t\t\t\t20180915041322_CIT0060","volume-title":"Zostavax SmPC","author":"Electronic Medicines Compendium (eMC)"},{"key":"key\n\t\t\t\t20180915041322_CIT0061","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t20180915041322_CIT0062","first-page":"729","article-title":"Update on recommendations for use of herpes zoster vaccine","volume":"63","author":"Hales","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20180915041322_CIT0063","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180915041322_CIT0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180915041322_CIT0065","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1053\/j.gastro.2003.09.029","article-title":"Mortality in inflammatory bowel disease: a population-based cohort study","volume":"125","author":"Card","year":"2003","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180915041322_CIT0066","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180915041322_CIT0067","first-page":"540","article-title":"Vaccinating patients with inflammatory bowel disease","volume":"12","author":"Reich","year":"2016","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"key\n\t\t\t\t20180915041322_CIT0068","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1097\/MIB.0000000000000743","article-title":"Herpes zoster vaccine response in inflammatory bowel disease patients on low-dose immunosuppression","volume":"22","author":"Wasan","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0069","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/apt.14257","article-title":"Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications","volume":"46","author":"Khan","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180915041322_CIT0070","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0071","volume-title":"XELJANZ summary of product characteristics","author":"Pfizer Inc"},{"key":"key\n\t\t\t\t20180915041322_CIT0072","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/annrheumdis-2013-eular.368","article-title":"Evaluation of influenza and pneumococcal vaccine responses in rheumatoid arthritis patients using tofacitinib","volume":"72","author":"Winthrop","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0073","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0074","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/art.40187","article-title":"The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180915041322_CIT0075","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0076","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/infdis\/jit342","article-title":"Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine","volume":"208","author":"Levin","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180915041322_CIT0077","volume-title":"SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) suspension for intramuscular injection, highlights of prescribing information","author":"US Food and Drug Administration"},{"key":"key\n\t\t\t\t20180915041322_CIT0078","volume-title":"SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) suspension for injection","author":"Health Canada"},{"key":"key\n\t\t\t\t20180915041322_CIT0079","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180915041322_CIT0080","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180915041322_CIT0081","volume-title":"GSK presents positive results from phase III revaccination study of its candidate shingles vaccine Shingrix at CDC\u2019s Advisory Meeting","author":"GlaxoSmithKline"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/24\/10\/2173\/25738972\/izy150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T16:01:47Z","timestamp":1751644907000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/10\/2173\/4998802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,17]]},"references-count":81,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,5,17]]},"published-print":{"date-parts":[[2018,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izy150","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10]]},"published":{"date-parts":[[2018,5,17]]}}}